Eversept Partners LP Sells 67,765 Shares of NewAmsterdam Pharma Company N.V. $NAMS

Posted by Stanley Muller on Jun 18th, 2026

Eversept Partners LP lessened its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Free Report) by 13.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 420,827 shares of the company’s stock after selling 67,765 shares during the period. Eversept Partners LP’s holdings in NewAmsterdam Pharma were worth $14,763,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. Frazier Life Sciences Management L.P. grew its holdings in shares of NewAmsterdam Pharma by 1.4% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 16,943,774 shares of the company’s stock worth $594,388,000 after purchasing an additional 241,818 shares during the last quarter. Capital World Investors grew its holdings in shares of NewAmsterdam Pharma by 1.6% during the fourth quarter. Capital World Investors now owns 9,984,000 shares of the company’s stock worth $350,239,000 after purchasing an additional 161,289 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of NewAmsterdam Pharma by 21.0% during the third quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock worth $114,332,000 after purchasing an additional 697,129 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its holdings in shares of NewAmsterdam Pharma by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after purchasing an additional 1,062,359 shares during the last quarter. Finally, Polar Capital Holdings Plc grew its holdings in shares of NewAmsterdam Pharma by 15.6% during the third quarter. Polar Capital Holdings Plc now owns 2,911,634 shares of the company’s stock worth $82,807,000 after purchasing an additional 393,855 shares during the last quarter. Institutional investors own 89.89% of the company’s stock.

Insider Activity

In other news, CAO Louise Frederika Kooij sold 65,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the transaction, the chief accounting officer owned 24,353 shares of the company’s stock, valued at $869,158.57. This represents a 72.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 12.74% of the stock is owned by company insiders.

NewAmsterdam Pharma Stock Down 0.1%

Shares of NAMS opened at $30.15 on Thursday. NewAmsterdam Pharma Company N.V. has a 12-month low of $17.63 and a 12-month high of $42.21. The firm has a market capitalization of $3.52 billion, a PE ratio of -16.84 and a beta of 0.07. The stock’s fifty day simple moving average is $33.26 and its 200-day simple moving average is $33.42.

NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The firm had revenue of $3.04 million for the quarter. Analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.78 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on NAMS shares. Truist Financial started coverage on NewAmsterdam Pharma in a report on Wednesday, March 18th. They set a “buy” rating and a $57.00 target price on the stock. Guggenheim increased their target price on NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NewAmsterdam Pharma in a research note on Thursday, February 19th. Finally, Needham & Company LLC upped their price target on NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $48.60.

Check Out Our Latest Analysis on NAMS

About NewAmsterdam Pharma

(Free Report)

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.